NCT03121339View on ClinicalTrials.gov

Pharmacodynamic Open-Label Trial With VXA-A1.1 Oral H1 Vaccine in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

March 31, 2017

Primary Completion Date

May 5, 2017

Study Completion Date

April 3, 2018

Conditions
Seasonal Influenza Preventative Vaccine Pharmacodynamics
Interventions
BIOLOGICAL

VXA-A1.1 H1 Tablet Vaccine (small)

Tableted oral H1 vaccine (\~140 mg tablet)

BIOLOGICAL

VXA-A1.1 H1 Tablet Vaccine (large)

Tableted oral H1 vaccine (\~275 mg tablet)

Trial Locations (1)

40504

Scintipharma, Inc., Lexington

Sponsors

Lead Sponsor

Vaxart
All Listed Sponsors
lead

Vaxart

INDUSTRY

NCT03121339 - Pharmacodynamic Open-Label Trial With VXA-A1.1 Oral H1 Vaccine in Healthy Adults | Biotech Hunter | Biotech Hunter